Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Commentary|Articles|April 23, 2026
FAQ: Insights on On-Body Injector for Anti-CD38 in Multiple Myeloma
Author(s)Jonah Feldman, Sikander Ailawadhi, MD
Fact checked by: Andrea Eleazar, MHS
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.
Advertisement
Advertisement
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending the approval of subcutaneous (SC) administration of isatuximab (Sarclisa).1 Although it is not the first subcutaneous therapy in multiple myeloma, the use of an on-body injector (OBI) in the supporting phase 3 IRAKLIA trial (NCT05405166) gives the topic of subcutaneous administration even greater promise to improve patient convenience.
Related to this article
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.
During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.
Advertisement
Advertisement